LRIG3 represses cell motility by inhibiting slug via inactivating ERK signaling in human colorectal cancer. Issue 7 (27th February 2020)

• Record Type: Journal Article
• Authors: Zeng, Kaixuan; Chen, Xiaoxiang; Xu, Mu; Liu, Xiangxiang; Li, Chenmeng; Xu, Xueni; Pan, Bei; Qin, Jian; He, Bangshun; Pan, Yuqin; Huiling, Sun; Xu, Tao; Wang, Shukui
• Is Part Of: IUBMB life. Volume 72:Issue 7(2020)
• Page Start: 1393
• Page End: 1403
• Publication Date: 2020-02-27
• Subjects: colorectal cancer -- EMT -- ERK signaling -- LRIG3 -- metastasis; Biochemistry -- Periodicals; Molecular biology -- Periodicals; 572.8
• DOI: 10.1002/iub.2262
• Languages: English
• ISSNs: 1521-6543

Abstract

Abstract: Metastasis is responsible for 90% of colorectal cancer (CRC)‐related deaths. In the present study, we identified a novel key regulator of CRC metastasis, leucine‐rich repeats and immunoglobulin‐like domains protein 3 (LRIG3), which was significantly decreased in CRC tissues and cell lines. Downregulation of LRIG3 was attributed to copy number loss and promoter hypermethylation. Low LRIG3 expression was positively correlated with metastatic clinical features and shorter survival time. Functional experiments showed that knockout of LRIG3 markedly enhanced CRC cell migration and invasion ability, whereas reintroduction of LRIG3 exerted the opposite effects. Regarding the mechanism, LRIG3 could facilitate the binding of DUSP6 to ERK1/2, resulting in the dephosphorylation of ERK1/2 and subsequently downregulation of slug, an epithelial‐to‐mesenchymal transition trigger, thereby constraining CRC cell motility. Importantly, LRIG3 expression was strongly negatively correlated with slug or p‐ERK1/2 expression in CRC tissues. Collectively, our data suggest that LRIG3 is a novel suppressor of CRC metastasis, reactivation of LRIG3 may be a promising therapeutic approach for metastatic CRC patients.